Communicated by Earl P. Benditt, February 7, 1991 ABSTRACT Proliferation of smooth muscle cells (SMCs) represents an important event in vascular lesion formation. Despite the common belief that growth factors contribute to the development of the atherosclerotic plaque, until now there has been no direct evidence for a role of mitogens in the development of arterial lesions. Balloon catheter injury of the rat carotid artery is accompanied by death of medial SMCs and is typically followed by proliferation of SMCs with subsequent formation of an intimal lesion. Our hypothesis is that injury causes mitogens to be released from dead cells, which then stimulate cell proliferation. One such mitogen that may be important in this process is basic fibroblast growth factor (bFGF), which can be detected immunocytochemically in SMCs and endothelial cells of adult rat carotid arteries.
Systemic injection of a neutralizing antibody against bFGF prior to balloon catheterization significantly decreased the induced SMC proliferation by -80%. The intimal lesion that developed within 8 days after injury, however, was not significantly reduced. The results of this study support the concept that endogenous bFGF is the major mitogen controlling the growth of vascular smooth muscle cells following injury. These data may have implications for the observed failure of endarterectomy and angioplasty procedures.
The proliferation of smooth muscle cells (SMCs) with subsequent formation of an intimal thickening is a major event in the development of atherosclerotic lesions (1) and is thought to contribute to restenosis of arteries following balloon angioplasty and endarterectomies (2) (3) (4) . Although several growth factors are thought to be involved in these processes, there are currently no data as to which factors are important for the proliferation of SMCs in vivo. Recent data from this laboratory have shown that mitogens from platelets alone cannot explain the proliferative response in balloon catheterinjured arteries (5) since SMC proliferation occurred in the absence of platelets (6) . In another study, the extent of SMC proliferation, however, was found to correlate with the severity of trauma inflicted by the denuding technique to the arterial wall (7) , which suggested a role for endogenous factors possibly released from injured cells within the vessel wall. The aim of this study was to seek evidence whether basic fibroblast growth factor (bFGF) was responsible for the initiation of SMC proliferation seen after vascular injury. Our data show that injection of an antibody against bFGF prior to balloon catheter denudation caused a significant decrease in the subsequent SMC proliferation.
MATERIALS AND METHODS
Anti-bFGF Antibody. Rabbits were immunized with pharmaceutical grade human recombinant bFGF, which was a generous gift from Synergen (Boulder, CO). Preimmune serum was obtained from female New Zealand rabbits ( (8) . Briefly, a lysate of a rat aorta, of which the endothelium and the adventitia had been removed, was analyzed by sodium dodecyl sulfate/polyacrylamide (15%) gel electrophoresis under reducing conditions (3% of soluble protein from one thoracic aorta was loaded per lane). After transfer to nitrocellulose, the blots were incubated with anti-bFGF IgG (12 ,tg/ml).
The effect of the anti-bFGF antibody was tested on proliferation of 3T3-D1 cells in response to 5 ng each of bFGF, platelet-derived growth factor [BB-homodimer (PDGF-BB); Zymogenetics, Seattle], epidermal growth factor (EGF; Collaborative Research), and calf serum (5%). 3T3-D1 cells are a subclone of Swiss mouse 3T3 fibroblasts and were plated at a density of 4 x 104 cells per well in a 24-well tray in Dulbecco's modified Eagle's medium supplemented with 10% calf serum. After 3 days, the cells reached confluence and were made quiescent by incubation in medium containing 0.5% calf serum for an additional 2 days before addition ofthe growth factors. The above mentioned growth factors were preincubated (10 min at 370C) with either anti-bFGF IgG or nonimmune IgG at 100 ,ug/ml followed by incubation with the 3T3 cells for 20 hr.
[3H]Thymidine (6.7 mCi/mmol; 1 Ci = 37 GBq; DuPont/New England Nuclear) was added to the cells (1 ,uCi/ml, 1 x 105 cells per well) and 2 hr later incorporation into DNA of the cells was measured in a liquid scintillation counter as described (9) .
Immunocytochemistry. Immunolocalization of bFGF in rat carotid arteries was carried out in vessels that had been perfused-fixed in situ for 4 min with phosphate-buffered (0.1 M, pH 7.4) paraformaldehyde (4%). Cryostat sections of rat carotid arteries were preincubated with 2% normal goat serum to prevent nonspecific binding of rabbit IgG. For these studies, the antibody raised against human recombinant bFGF was affinity purified using human recombinant bFGF coupled to Affi-Gel 10 (Bio-Rad). This affinity-purified antibody was used at a concentration of 3 /ug/ml. Incubations were carried out as described (10) using a biotinylated goat Abbreviations: SMC, smooth muscle cell; bFGF, basic fibroblast growth factor; EGF, epidermal growth factor; PDGF, plateletderived growth factor. *To whom reprint requests should be addressed.
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anti-rabbit IgG (1:400 dilution) and ABC-Elite kit (both from Vector Laboratories). All incubations lasted 30 min and were carried out at room temperature. Corresponding concentrations of nonimmune IgG were included as controls.
Experimental Protocol. Three-to 4-month-old SpragueDawley rats (Tyler Laboratories, Bellevue, WA) weighing 280-340 g were used. All surgery was performed under general anesthesia with an initial intramuscular injection of 0.06 mg of fentanyl per kg (Innovar-Vet; Pitman-Moore, Mundelien, IL) and additional injections when necessary. Anesthesia with ether was chosen for tail vein injections. Ten milligrams of protein G-purified antibody per animal was injected into the tail vein immediately prior to removal of the endothelium by a nontraumatic procedure using a filament loop (7, 11) , thereby facilitating the penetration of antibody into the vessel wall. Five minutes after endothelial denudation, balloon catheterization of the same vessel was performed as described (5) . Five additional intravenous injections of antibody (each 2.5 mg of IgG) were given every 8 hr until the experiment was terminated. Control animals were treated in an identical fashion with the exception that matching concentrations of nonimmune IgG were injected at the same times. At 24, 32, and 40 hr after balloon catheter injury, all animals were injected with [3H]thymidine (50 ,uCi/100 g of body weight, 6.7 mCi/mmol; New England Nuclear) and 41 hr after injury they were killed with an overdose of sodium pentobarbital (160 mg/kg of body weight). Fixation for 5 min by perfusion with 4% paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.4) was followed by excision of the carotid arteries and overnight immersion fixation. The tissue was processed for determination of proliferation rates of SMCs.
An experiment was carried out in another set of animals following the identical protocol as described above with the exception that only one injection of anti-bFGF antibody or nonimmune IgG (10 mg) was injected prior to endothelial denudation. The rats were sacrificed 41 hr after balloon catheterization and the tissue was processed as described above.
The effect of the anti-bFGF antibody on formation of intimal thickening after balloon catheter injury was studied in an additional experiment. A single injection of antibody or nonimmune IgG (10 mg) before balloon catheterization of the left carotid artery was administered as described above.
Eight days after balloon injury the animals were perfusion fixed and the carotid arteries were processed for measuring intimal SMC Proliferation and Intimal Thickening. Two segments ofthe central portion (8 mm apart) ofthe carotid arteries were embedded in paraffin and cross sections were cut. For determination of SMC replication, the sections were prepared for autoradiography as described earlier (12) . The number of labeled nuclei was counted and the [3H]thymidine index [(labeled nuclei/total nuclei) x 100] was calculated.
The cross-sectional areas of carotid intima were obtained from hematoxylin-stained paraffin sections. Cross-sectional images were traced on a digitizing pad (GTCO, Rockville, MD) using a camera lucida (Leitz) and intimal areas were calculated with a software package (Image Measure; Microscience, Seattle).
Statistics. All data were analyzed by using Student's t test. Data were considered significant if P < 0.05.
RESULTS
Specificity of the Anti-bFGF Antibody. The antibody raised against bFGF recognized recombinant bFGF and a single protein band in an immunoblot assay of rat arterial lysate with an apparent molecular mass of 18 kDa (Fig. 1) . IgG fractions purified from the antiserum were found to neutralize the mitogenic effect of recombinant human bFGF added to 3T3-D1 cells (Fig. 2) . This antibody did not reduce the mitogenic response from the addition of either PDGF-BB, EGF, or calf serum to these cells (Fig. 2) tor and had no effect on the initial platelet adherence to the denuded arteries (data not shown).
ImmunocytochemAstry. We had previously demonstrated the presence of bFGF in the vessel wall of rat arteries by immunoblot analysis (8) but had no evidence of its cellular localization. Using the affinity-purified antibody described above, immunolocalization of bFGF in rat carotid arteries was carried out in vessels that had been perfused-fixed in situ. Cryostat sections incubated with this antibody showed a predominantly nuclear staining of endothelial cells and medial SMCs (Fig. 3) . In these sections no staining of the extracellular compartment was observed.
Medial SMC Proliferation. The anti-bFGF antibody was then used to inhibit the in vivo proliferative response ofSMCs induced by balloon catheter injury. The neutralizing antibody to bFGF was administered systemically (10 mg of protein G-purified IgG) prior to balloon catheter denudation of the carotid artery, and five additional intravenous injections of antibody (2.5 mg of antibody per animal) were given every 8 hr until the experiment was terminated. Control animals were treated in an identical fashion with the exception that matching concentrations of nonimmune IgG were injected at the same times. The proliferation of medial SMCs measured 41 hr after balloon catheter injury by [3H]thymidine index (Fig.  4) was significantly reduced in those animals that received the anti-bFGF antibody (1.5% versus 7.6% in controls). In an additional experiment we investigated whether a single injection of the antibody given immediately prior to injury would be sufficient to neutralize any bFGF and so inhibit SMC proliferation. We argued that if balloon catheterization caused cell injury and death, then release of bFGF would likely occur rapidly, rendering continued administration of the antibody unnecessary to inhibit SMC replication. This experiment was carried out using the same protocol as described above with the exception that only a single injection of either anti-bFGF IgG or preimmune IgG ( animal) was administered intravenously before balloon catheter injury. As shown in Fig. 4 the proliferation of medial SMCs was reduced to a similar extent following a single injection of anti-bFGF antibody (1.4% versus 16.8% in controls), although the control group showed a higher proliferative response than observed after repeated injections of the nonimmune IgG. Presently we cannot explain why repeated injections of nonimmune IgG caused a decrease in SMC proliferation. Intimal Lesion Formation. The medial SMC proliferation that occurs after balloon catheter denudation of the carotid artery is also accompanied by migration of SMCs into the intima. Within days after denudation, a combination of cell migration and persistent intimal proliferation leads to formation of intimal lesions (12) . It was therefore of interest to determine whether inhibition of medial SMC proliferation after injury would influence formation ofthese lesions. In this experiment, rats received one intravenous injection of antibFGF or nonimmune IgG (10 mg) prior to balloon injury as described above and 8 days after injury the animals were sacrificed. The intimal thickening of the denuded carotid artery was determined by measuring the intimal area on cross sections of the vessel (8) . Compared to controls, no significant reduction in intimal lesion size was observed in rats that received the anti-bFGF antibody (Fig. 5) .
DISCUSSION
It has been unclear as to which factors control SMC proliferation in the arterial wall induced by vascular injury since our recent studies suggested that platelet factors do not play a role in initiating this proliferative response (6) (7) (8) 13) . We have previously found bFGF to be present in the vessel wall of rat arteries (8) by immunoblot analysis and several authors have demonstrated bFGF to be present in various rat fetal and adult tissues (14) (15) (16) (17) (18) (19) (20) (21) . In this study, using an affinitypurified antibody to bFGF, we observed that in the uninjured artery, bFGF appears to be localized in endothelial cells and SMCs and is apparently concentrated in the nucleus of these cells. Using light microscopy, however, it was not possible to precisely identify its location. Nevertheless, these data illustrate the fact that there is a pool of bFGF in the arterial wall and if cell injury and cell death occur, then this mitogen could be released and act on surrounding cells. Balloon catheterization has been shown to cause widespread cell death (12) , and thus under these circumstances intracellular factors would be released. Our wish to emphasize that not all antibodies raised against this mitogen were effective and only those proven to neutralize bFGF-induced cell proliferation in vitro were capable of blocking the SMC response in vivo.
In light of the above results, it was surprising to find that the neutralizing antibody for bFGF had no effect on the development of the arterial lesion. One explanation for this finding is that the antibody would only neutralize free unbound bFGF and matrix-bound bFGF would therefore be inaccessible. In this study, a single injection of the antibody was given immediately after injury. The kinetics of bFGF release from extracellular sites are unknown and, consequently, any release of bFGF at later times would not be inhibited by the antibody. Of relevance to this issue is the finding that plasmin can release bFGF from the matrix (22), and we and others have found that plasminogen activator activity is significantly increased several days after balloon catheter injury (23, 24) . Therefore, matrix-bound bFGF might be released and exert a mitogenic effect several days after injury (25) . Another possible explanation is that smooth muscle cell migration and the subsequent intimal cell proliferation are controlled by factors other than bFGF, and of interest is the recent finding that intimal smooth muscle cells can express PDGF-A chain after balloon catheter injury (26) .
The data presented in this study are important because they illustrate one possible in vivo pathway of how SMCs can be stimulated to proliferate. It also helps to explain why differing vascular injuries have been reported to cause a wide variety of responses by SMCs. In general, it would appear that injuries that caused little or no trauma to the medial cells elicited a small or no response in terms of SMC proliferation (7, 27, 28) . In contrast, balloon catheterization and other injuries that cause widespread cell death are followed by significant increases in SMC replication (12, 29, 30) . These data might have important implications in certain clinical situations, such as angioplasty, where rapid SMC growth is frequently a serious complication. Further, a role for bFGF in the progression of atherosclerotic lesions could occur by means of the described mechanism since cell necrosis (31) and increased cell turnover (32) are found in atherosclerotic lesions.
